Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: Michael Postow, Jason Chesney, Anna Pavlick, Caroline Robert, Kenneth Grossmann, David McDermott, Gerald Linette, Nicolas Meyer, Jeffrey Giguere, Sanjiv Agarwala, Montaser Shaheen, Marc Ernstoff, David Minor, April Salama, Matthew Taylor, Patrick Ott, Joel Jiang, Christine Horak, Paul Gagnier, Jedd Wolchok, F. Stephen Hodi
Institutions: Memorial Sloan Kettering Cancer Center, University of Louisville, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Inserm, Institut Gustave Roussy, University of Utah, Huntsman Cancer Institute, Beth Israel Deaconess Medical Center, Washington University in St. Louis, Prisma Health, St. Luke's University Health Network, University of New Mexico, Cleveland Clinic, California Pacific Medical Center, Duke University, Oregon Health & Science University, Dana-Farber Cancer Institute, Bristol-Myers Squibb (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2480214640